NVAXNot financial advice.
The essence of investing & trading is the intelligent and patient preying on the greed, fear, impatience, addiction and ignorance of the majority. It's definitionally Darwinian.
NVAX trade ideas
NVAX - Novavax Biotech Short or not?NVAX as seen on the weekly chart has been in price distress for a long time.
It has only one product on the market due to various issues with the FDA process.
It has a variety of products in development as linked below.
The question is whether it will run out of cash before a sustained revenue
stream develops. FDA approvals for the pipeline products could take years
( the days of emergency approvals for COVID and related are over)
It would seem that a rich uncle like Moderna ( MRNA) would codcme
around with a take-over offer that could send shares into a moonshot
to back when NVAX thrived before its 95% price decline in the past two
years. This seems to be a great short swing play until more products come
to market or a take-over is announced. This is affirmed by the MACD
histogram being persistently negative for the long-term.
NVAX Text book bearish Shark patternHi guys, NVAX showed up on my feed today as down 25% so I decided to take a look. What I see is a text book Bearish Shark attack on the stock. Looking at the embedded image in this chart you can compare the events as they occurred. The stock price has also gone back to beginning of the rally.
Please do your DD this is not a financial advice.
$NVAX: Low risk buy signalNice long setup in $NVAX here, you can expect a decent advance if it holds over $10.75.
Best of luck!
Cheers,
Ivan Labrie.
NVAX to at least 19If it can complete a structure I am looking for then it can potentially run to 30s best case, but more likely 19-22. Worst case it has downside risk to 4 if this structure falls apart.
Rejection from re-entering blue channel would imply the latter. Good news would be necessary for the best case.
The more likely case is just a technical gap fill - would happen fast and then either squeeze or shatter.
Selling NVAX in corrective channel.Novavax - 30d expiry - We look to Sell at 27.69 (stop at 30.03)
The primary trend remains bearish.
Trading within a Corrective Channel formation.
The trend of higher highs is located at 26.80.
Previous support at 27.40 now becomes resistance.
We look for a temporary move higher.
Preferred trade is to sell into rallies.
Our profit targets will be 22.02 and 21.02
Resistance: 21.60 / 23.00 / 25.30
Support: 18.26 / 16.86 / 16.00
Disclaimer – Saxo Bank Group.
Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
Novavax in a bear flag.Novavax - 30d expiry - We look to Sell a break of 15.49 (stop at 17.01)
Daily signals are bearish.
There is no clear indication that the downward move is coming to an end.
Prices are extending lower from the bearish flag/pennant formation.
Posted a bearish Flag formation.
A break of 15.50 is needed to confirm the outlook.
The bias is to break to the downside.
This stock has seen poor sales growth.
Our outlook is bearish.
Our profit targets will be 12.12 and 11.62
Resistance: 18.00 / 18.55 / 19.50
Support: 16.30 / 15.53 / 15.00
Disclaimer – Saxo Bank Group.
Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
Novavax NVAX Accumulation or distribution? Wychoff wants to know! Phase C, Spring Stage? M.Cap is below CASH, Best in Class vaccine with over 43+ International Approvals.
It’s just amazing what Nova’s teams have be able to accomplish(for its size) around the globe!
NVAX ready to rallyNVAX is at the bottom of the fib channel right now with stochastic at interesting levels. I'm bullish and buying Jan calls with strikes $80 and up.
NVAX ready to begin next bullish cycleNear term (1-2 weeks): target range 25-28
1-2 months: 45 range
Goal target (Q1 or Q2 2023): 163
Historical pattern is cyclical, with 7 completed alternating cycles between 20 and >=163
Signs of strength NVAXSome signs of strength for NVAX. The trend has more work in order to change but it is going really well.
NVAX | Lets Get It | OversoldNovavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Looking for a reversal in fortune for NOVAVAX Short Term
We look to Buy at 30.75 (stop at 26.75)
Bullish Outside Day posted, a pattern that often indicates the end of a bearish run and the start of a new upward bias. Prices have continued the bullish move higher and resulted in 3 consecutive positive days. Although the bears are in control, the stalling negative momentum indicates a turnaround is possible. In line with the possible early stages of a reverse head & shoulders pattern and the strong rejection of dips, we look to set longs in anticipation of a swing higher.
Our profit targets will be 42.75 and 47.70
Resistance: 37.92 / 44.52 / 47.70
Support: 28.30 / 24.00 / 20.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
Update on Wyckoff accumulation chartUpdate on Wyckoff accumulation chart. Volume is decreasing. A low-volume spring (or a low-volume test of a shakeout) indicates that the stock is likely to be ready to move up, so this is a good time to initiate at least a partial long position.
Bullish hammer on Novavax?Novavax
Short Term
We look to Buy at 35.94 (stop at 32.00)
Posted a Bullish Hammer Bottom on the Daily chart. Although the anticipated move higher is corrective, it does offer ample risk/reward today. We therefore, prefer to fade into the dip with a tight stop in anticipation of a move back higher. Expect trading to remain mixed and volatile.
Our profit targets will be 49.43 and 60.00
Resistance: 45.00 / 63.00 / 76.00
Support: 35.00 / 23.12 / 15.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
Is NVAX oversold following its earnings miss?A few days ago, NVAX gapped down 30 percent on a large earnings miss. This means that now NVAX is down over 87% from its ATH.
Why I think NVAX is a buy right now
The stock had a minor rally off a long term support level extending to 2020, and has higher lows than during the previous rally off this support level. It is trading at a heavily discounted price/sales of 2.55, far below its peak p/s at 249.16. There is a large upside, with the nearest strong resistance level roughly 50% above the current price.
I'm buying in at around 42.2 with a high risk reward ratio. I'll be targeting a roughly 20% return with a 5% stop.
this vaccine trade popped in february 2021, can it recover some?all gas no breaks with a full tank and a full trunk. this covid vaccine stock enjoyed a huge runup to the release of the vaccine, but since has languished on the monthly as it lost over 90% of the price high. im not looking towards this as a long term investment, but im buying the rumor that nvax is announcing new trials or a variant innoculation or at least some catalyst and selling the news of that catalyst as well as the release of the vaccine/start of trial. if we stay above pivot, im aiming for upper horizontals and if we fall beneath it im looking for the lower horizontals. im not looking for a huge long on this thing, just maybe some monthly snap back and a move to close gap.
NVAX - The FDA finaleI reworked on my chart last night and this morning the high and lows of the day seem to fall in place.
I expect us to get approved on Thursday which bring the SP to $95 and $100 on Friday. Some pullbacks after but eventually we reach $140 on the 26th.
Let's see how everything pans out. Good luck to the NVAX'ers.
NVAX… once a loser always a loserthe inability of NVAX to properly capitalize on the covid vaccine is a sign of a poorly managed company. was the rise from near penny status exceptional? of course. was the following wealth destruction of epic proportions? sure was.
endless upset longs continue to exit as all good news acts as a selling event. this will be a ride back to single digits for a company who, pre-covid, could not get a single ball across the goal line.
NVAX Long -- Good ER expectation A small pull back to retest $56/57 pivot high, then spike towards $72/80.
Next quarter expectation should be good.
No Brainer Mid-Long TermEmphasizing the mid-long term reward outweighs the near-term risk here using statistics in confluence with wyckoff and corrective structure:
Here is what I see, accumulation began early 2022 and attempted a spring in April, but NVAX just didn't have the near-term catalysts it needed to follow through with a sign of strength (especially in the general corrective market environment of 2022).. so it began a new accumulation phase at lower levels. :
- I use control charts that I designed in R, which help me gauge the stability of the current price levels w.r.t. moving averages over near- to mid-term periods (long term NVAX is cyclical and that is a whole different monster, requires more sophisticated time series and beyond the scope of this post). The 4 different CCs in the pasted image in this chart are 4 different relationships that have provided me, in general, with good results when all 4 are consistent in their interpretation. What is important here is that for NVAX to continue trading at current levels would be an anomaly, statistically.. however, if it maintains these levels for extended periods then they would become the new norm (the latter is least probable here)
- downside risk near-term before NVAX become an extreme anomaly (which has 98% bounce rate, current level around 86%-93% bounce rate) is the 20-26 range
- near term tendency of price is to bounce to 52-63
- generally there is an equal and opposite reaction when a name gets this unstable down it will over compensate on the move up. Overcompensation range that I am actually expecting (catalyst will be approval, or whatever they conjur up to pump it, idc): 67-73
** Using confluence with ARIMA time series, wyckoff expectation of seeing an SoS here off this new spring that is forming, and dynamics of control charts (I use these to confirm accumulation or distribution as well), it would make most sense to see an over-reaction bounce soon centered around some hyped news to around 67-73, followed by a pullback into the stable range around 52, and then continuation from there. The yellow paths are just illustrative, solid line near term trajectory, dashed line the general mid-term expectation for price action.. again, illustrative for now.
